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MEETING REPORT
Clinical development of placental 
malaria vaccines and immunoassays 
harmonization: a workshop report
Arnaud Chêne1, Sophie Houard2, Morten A. Nielsen3,4, Sophia Hundt2, Flavia D’Alessio2, Sodiomon B. Sirima5, 
Adrian J. F. Luty6,7, Patrick Duffy8, Odile Leroy2, Benoit Gamain1 and Nicola K. Viebig2*
Abstract 
Placental malaria caused by Plasmodium falciparum infection constitutes a major health problem manifesting as 
severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. 
Prevention of placental malaria currently relies on two key strategies that are losing efficacy due to spread of resist-
ance: long-lasting insecticide-treated nets and intermittent preventive treatment during pregnancy. A placental 
malaria vaccine would be an attractive, cost-effective complement to the existing control tools. Two placental malaria 
vaccine candidates are currently in Phase Ia/b clinical trials. During two workshops hosted by the European Vaccine 
Initiative, one in Paris in April 2014 and the other in Brussels in November 2014, the main actors in placental malaria 
vaccine research discussed the harmonization of clinical development plans and of the immunoassays with a goal to 
define standards that will allow comparative assessment of different placental malaria vaccine candidates. The recom-
mendations of these workshops should guide researchers and clinicians in the further development of placental 
malaria vaccines.
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Background
People living in malaria endemic areas gradually develop 
immunity to clinical manifestations of Plasmodium fal‑
ciparum infection, and severe malaria is unlikely above 
5  years of age in areas of stable transmission [1]. How-
ever, during their first pregnancy, women become sus-
ceptible to placental malaria regardless of previous 
exposure to the parasite. Over 50 million women living in 
endemic areas are exposed every year to the risk of devel-
oping malaria during pregnancy. Placental malaria can 
have serious consequences for both mother and child [2, 
3] and is estimated to cause between 75,000 and 200,000 
infant deaths every year [4].
The currently recommended preventive strategies 
to reduce the risk of placental malaria are based on the 
use of insecticide-treated bed nets and the intermittent 
administration of anti-malarial drugs. Unfortunately, 
these approaches are now reaching their limits, becom-
ing progressively less effective due to the emergence of 
drug and insecticide resistance in the parasite and its 
vector, respectively. Women in endemic areas urgently 
need novel interventional methods. In areas of stable 
transmission, the prevalence and severity of placental 
malaria diminish with successive pregnancies [5, 6] dem-
onstrating that immunity is acquired as a result of natural 
infection, and supporting the prospects for a vaccine that 
protects pregnant women and their children from the 
dire consequences of placental malaria [7, 8].
Infected erythrocytes isolated from placentas of 
women (iRBCPM) present a unique adhesive phenotype. 
iRBCPM do not bind to the common receptors used by 
the parasite to adhere to the microvascular endothelium 
[9, 10], but rather bind to the glycosaminoglycan chon-
droitin sulphate A (CSA). Chondroitin sulphate proteo-
glycans are present in the placental intervillous space by 
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the end of the third month of gestation [11], when utero-
placental circulation is fully established, thus offering a 
potential anchor point for iRBCPM. VAR2CSA, which is 
expressed on the surface of iRBCPM, has been identified 
as the parasite-derived protein mediating the adhesion 
to placental CSA [12–15]. VAR2CSA is a high molecu-
lar weight protein, with a 300  kDa extracellular region 
organized in 6 Duffy-binding like (DBL) domains and 
cysteine-rich interdomain (ID) regions (CIDR). Recent 
studies have shown that a single CSA-binding site is 
formed by a higher-order domain organization involving 
multiple VAR2CSA domains [16, 17] and that the N-ter-
minal region plays a major role in CSA adhesion [18, 19], 
with the minimal binding domain located in ID1-DBL2-
ID2 [19].
The European Vaccine Initiative (EVI) [20] and its part-
ners have been instrumental in mobilizing funds for the 
development of a vaccine against placental malaria, through 
the PRIMALVAC (Institut National de la Santé et de la 
Recherche Médicale, Inserm, France) and PAMCPH (Uni-
versity of Copenhagen, UCPH, Denmark) projects funded 
by the German Federal Ministry of Education and Research 
through Kreditanstalt für Wiederaufbau, the Irish Aid and 
the Danish National Advanced Technology Foundation as 
well as the PlacMalVac (University of Copenhagen, Den-
mark) project funded under European Commission Seventh 
Framework Programme (FP7). Both, the PRIMALVAC and 
PAMCPH/PlacMalVac projects currently have VAR2CSA-
based vaccine candidates in Phase Ia/b clinical trials.
Although the two vaccine candidates are based on the 
same protein VAR2CSA, the selected antigens encom-
pass different VAR2CSA regions and sequences with 
potentially distinct antigenic properties that might com-
plement each other in terms of immunogenic potency 
and protective efficacy. While the PRIMALVAC pro-
ject has selected DBL1X–DBL2X, a 105-kDa domain of 
VAR2CSA from the P. falciparum strain 3D7 expressed 
as a recombinant protein in Escherichia coli (PRIM-
VAC), the PAMCPH/PlacMalVac projects focus on ID1-
DBL2X-ID2a, a 73-kDa derivative of VAR2CSA from the 
P. falciparum strain FCR3, produced as a recombinant 
protein in Drosophila melanogaster Schneider-2 (S2) cells 
[21] (PAMVAC). Both candidates entered clinical testing 
in May 2016. Each vaccine candidate will be assessed in 
a staggered Phase Ia/b clinical trial where the Phase Ia 
stage will start in malaria naïve populations in Europe, 
followed by Phase Ib stage targeting malaria endemic 
populations in Africa.
Aims of the workshops
In order to facilitate the harmonization of the clinical 
development of placental malaria vaccine candidates, 
EVI organized joint workshops on the 24th of April 2014 
at the Institut Pasteur, Paris, France and on the 19th of 
November 2014 in Brussels, Belgium.
The aim of the first workshop was to bring together the 
researchers involved in the PRIMALVAC, PAMCPH and 
PlacMalVac projects, including those implicated in the 
clinical trials in Europe and in Africa, as well as a panel 
of worldwide experts to establish the preferred product 
characteristics for a placental malaria vaccine, and to 
refine the clinical development plan and the design of 
the Phase I clinical trials. The second workshop aimed 
at initiating collaboration between the PRIMALVAC and 
PAMCPH/PlacMalVac teams to develop harmonized 
functional immunoassays that would allow comparison 
of preliminary immunogenicity analyses of the two pla-
cental malaria vaccine candidates under development. 
The outcomes of the workshops are summarized in this 
report.
Design of the Phase Ia/b clinical trials
Preferred product characteristics
In order to drive the vaccine development strategy, 
preferred product characteristics need to be defined, 
including target population, indications, route of admin-
istration, vaccination schedules, and the clinical data 
required to assess the safety and perform a preliminary 
efficacy analysis. The panel agreed that VAR2CSA-based 
vaccine candidates will be indicated to prevent the com-
plications of placental P. falciparum malaria in pregnant 
women, aiming to protect both the mother and the fetus. 
In early clinical development, the vaccine candidates 
should be administered to women from P. falciparum 
malaria endemic areas prior to their first pregnancy.
Owing to its simplicity and the expectation that malaria 
exposure during pregnancy will naturally boost protec-
tive responses, workshop attendees agreed that a single 
intramuscular immunization will be an ultimate goal, but 
at this early stage of development the need to assess the 
immune response profile supports a three dose regimen, 
potentially with a booster to ensure longevity of the pro-
tective immune response elicited by the vaccine. Because 
malaria prevalence has decreased in many communities, 
the impact of boosting by natural infection should be 
factored into vaccination schedules and efficacy analy-
ses. Furthermore, the age at the time of vaccination will 
be influenced by possible coordination or combination 
with other vaccines, e.g. vaccines against human papil-
loma virus (HPV), tetanus, rubella or booster of a future 
marketed paediatric malaria vaccine in young girls. The 
clinical development plan should document the absence 
of immunological or clinical interference with any co-
administered vaccines.
The clinical development of placental malaria vaccines 
should follow the clinical section of the World Health 
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Organization’s “Guidelines on the quality, safety and 
efficacy of recombinant malaria vaccines targeting the 
pre-erythrocytic and blood stages of P. falciparum” [22]. 
However, those guidelines are general and do not take 
into consideration the effects on the fetus and neonate, 
which should be included in the endpoints for evaluating 
the placental malaria vaccine candidates.
The endpoints and the case definition should include 
all episodes of malaria that meet the case definition, (1) 
clinical malaria is the presence of fever, defined as an 
axillary temperature of ≥37.5  °C, and (2) parasitological 
diagnosis based on a parasite density threshold quanti-
fied by microscopy with defined and accurate specificity 
and sensitivity. Severe malaria, co-morbidities, and effi-
cacy against infection are further defined in the guide-
lines, and should also be considered. Given that the most 
common presentation during pregnancy is of infection 
without overt clinical symptoms, it is likely that efficacy 
against placental infection and children birth weight will 
be prioritized endpoints.
Target groups and administration
Indication The vaccine is indicated for the prevention 
of the complications of P. falciparum placental malaria in 
pregnant women, and will offer protection to the mother 
and fetus.
Target population The intended population is nul-
ligravid females in areas with endemic P. falciparum 
malaria. Pregnant women are specifically excluded. 
Therefore, the vaccine will protect pregnant women, but 
will be administered before first pregnancy.
The dose regimen The vaccine will be administered in 
three intramuscular doses.
The potential for co‑administration The vaccine will ide-
ally be co-administered as a package for young girls with 
vaccines against HPV, tetanus and/or rubella, also poten-
tially future marketed paediatric malaria vaccine.
Safety and efficacy
The safety and reactogenicity should be comparable to 
recommended vaccines in immunization programmes in 
the endemic countries. There is not yet an accepted pro-
tection rate for a placental malaria vaccine, but the goal is 
that the placental malaria vaccine will reduce the incidence 
of placental malaria outcomes such as low birthweight to 
a similar degree as naturally acquired immunity in multi-
gravidae. The duration of protection is very important as 
the time to pregnancy after vaccination could be several 
years; the period during which naturally occurring boost-
ing occurs should be an endpoint for evaluation.
Clinical development plan
The aim of this workshop was to establish at least an 
outline of a clinical development plan. The clinical 
development plans for both projects were considered in 
three stages, namely Phase I clinical trials assessing the 
safety and immunogenicity in healthy adult populations. 
After meeting critical safety and immunogenicity end-
points discussed above, a series of Phase II clinical tri-
als will enroll an exclusively nulligravid adolescent/adult 
endemic population and assess additional immunological 
endpoints and preliminary efficacy markers. These clini-
cal trials will involve a significantly larger population. If 
the vaccine candidate shows promising safety, immu-
nogenicity and efficacy results then it can be moved 
to Phase III clinical trials involving a larger nulligravid 
endemic target population.
The panel agreed that the fast track strategy designed 
by EVI and its partners could be applied to Phase I clini-
cal trials and even later Phase clinical trials to accelerate 
clinical development. This fast track strategy allows for 
Phase I clinical trials to be reduced to one single stag-
gered Phase Ia/Ib clinical trial where the Phase Ia stage of 
the clinical trial starts in healthy adult males and females 
from a malaria non-endemic population, and the Phase 
Ib stage is restricted to the targeted healthy nulligravid 
endemic population. As Phase IIa challenge studies are 
not feasible for the evaluation of the efficacy of placen-
tal malaria vaccine candidates, the fast track strategy will 
allow a fast transition to the target population. The age 
range of the nulligravid subjects in an endemic region 
will span from the national age of majority in the country 
hosting the clinical trial to the upper age limit of 35 years, 
with the expectation that few nulligravid women will be 
older than this in the target population.
The Phase II clinical trials will include assessment of 
dosage, formulation, age group de-escalation, and inter-
action with other vaccines. Depending on the results, 
additional Phase I or even pre-clinical studies may be 
required.
Decision criteria
In terms of the safety requirements for transition from 
the Phase I stage in non-endemic region (Phase Ia) to 
the Phase I stage in endemic region (Phase Ib) of the first 
clinical trial, there should be no serious adverse events 
definitely related to the vaccine candidate, and serious 
adverse events possibly related to the vaccine candidate 
or grade 3 adverse events lasting for more than 48  h 
should be reviewed by the independent safety monitor-
ing board appointed for the clinical trial with recom-
mendation made to the sponsor. The phase Ib data will 
be evaluated for both safety and immunogenicity, and 
the threshold criterion for further clinical development 
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requires at least 60 % seroconversion against the vaccine 
candidate antigen in the target population. The major 
outcomes on the clinical development plan are depicted 
in Table 1.
Design of the Phase Ia/b clinical trials
Based on the recognized need to have harmonized clini-
cal trials that would allow comparison of the Inserm and 
UCPH vaccine candidates, the rationale for the design of 
the Phase Ia/b clinical trials was discussed.
The panel agreed the clinical trials will be randomized 
and double blinded if possible, with due consideration of 
the technical and logistic constraints at the trial sites. The 
vaccine antigen dosage was discussed. It was anticipated 
from previous malaria clinical trials results with recom-
binant antigens in adult populations that the appropriate 
dosage will be around 50 µg per dose. The vaccine antigen 
will be mixed with the selected adjuvant. The adjuvants 
will include aluminium hydroxide as reference adjuvant 
as it is widely used in approved vaccines and easily avail-
able. The other adjuvant will be a novel adjuvant that is 
expected to provide better immunogenicity. The Phase 
Ia clinical trial stage in Europe will comprise two dosage 
groups, one given 20 µg of the vaccine antigen (n = 2–3) 
and the other given 50 µg (n = 6–10), in both cases with 
aluminium hydroxide and/or a novel adjuvant. The Phase 
Ib stage of the clinical trial will proceed if safety thresh-
olds in the European arms are met and will also comprise 
two dosage groups, one at 50 µg and one at 100 µg (each 
n = 6–10) in both cases with aluminium hydroxide and/
or the novel adjuvant. The Phase Ib clinical trial stage in 
Africa will also include a saline placebo group. Saline pla-
cebo was chosen instead of HPV vaccine as the dosage 
schedule selected (0, 1 and 2  months) is not appropri-
ate for the HPV vaccine. However, HPV vaccine offered 
to all subjects enrolled in the Phase Ib after completion 
of the clinical trial would be an appropriate benefit to 
participants.
Potential inclusion/non-inclusion criteria were defined. 
The main inclusion criteria for Phase Ia stage in Europe 
will be healthy adult females willing to practice contra-
ception and adult males. The main inclusion criteria in 
Africa will be healthy nulligravid female adults living in 
malaria endemic areas willing to practice contraception 
for the duration of the vaccinations and a defined fol-
low-up period. The main non-inclusion criteria include 
pregnancy, concurrent infection with malaria, known 
HIV-positive status and known carriers of Hepatitis B 
(HBV) or Hepatitis C (HCV). The subjects will be fol-
lowed for six months after the last dose to assess vac-
cine safety as per regulatory guidelines and to gather 
the appropriate immunological and (if possible based 
on assay development standards) functional data on the 
performance of the vaccine candidate. As pregnancy 
outcome in malaria endemic areas could be informative 
on preliminary efficacy of the vaccine, the protocol and 
the subject informed consent form should mention that 
pregnancy outcome information occurring after trial 
completion could be disclosed to the vaccine trial unit, 
contingent on the subject’s agreement. The primary end-
point of the Phase Ia/Ib clinical trial was confirmed as 
safety and a minimal 60 % seroconversion to meet the go 
criterion for further clinical development (i.e. to proceed 
with Phase II b clinical trial). The major outcomes on the 
design of the Phase Ia/Ib trials are depicted in Table 2.
Immunoassays
The parallel conduct of two clinical trials with two dif-
ferent VAR2CSA-based vaccine candidates represents a 
unique opportunity to better understand the immuno-
logical processes by which protection against placental 
malaria can be achieved, particularly humoral immune 
responses that play the central role during the erythro-
cytic stage of the infection. The harmonization of the 
relevant immunoassays across the concurrent placental 
malaria vaccine projects is thus fundamental to predict 
and compare the efficacy of the different vaccines and to 
define go/no go criteria for the design and development 
of Phase II clinical trials.
Evaluation criteria
In high P. falciparum transmission settings, women grad-
ually acquire immunity to placental malaria following 
successive pregnancies [5] and primigravid women are 
at higher risk of developing placental malaria with more 
severe adverse consequences than multigravid women. 
This progressive protection has been associated with the 
acquisition of antibodies able to recognize the surface 
Table 1 Major outcomes on the clinical development plan
• Phase Ia and Ib clinical trials could be a single Phase I staggered clinical trial
• The Phase Ia stage of the clinical trial would be in adults from malaria non-endemic population in Europe and the Phase Ib stage would target nul-
ligravid adults from endemic population
• Phase II clinical trials will target nulligravid women from an endemic region and will include dose escalation, age group de-escalation, and exploratory 
data on interactions with other vaccines
• Phase III clinical trials would be in the target nulligravid population in endemic region
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of iRBCPM [10, 23, 24] and more specifically the para-
site-derived protein VAR2CSA [13, 25]. Furthermore, 
antibodies blocking the adhesion of placenta-derived 
P. falciparum infected erythrocytes to CSA have been 
shown to reduce the prevalence of placental malaria [23] 
and have also been linked to improved pregnancy out-
comes [26]. Of major importance, antibodies from multi-
gravid women are able to block the interactions between 
CSA and iRBCPM originating from different parts of the 
world, demonstrating the existence of a strain-transcend-
ing effective immune response to placental malaria and 
suggesting a relative conservation of the parasite-derived 
CSA ligand(s) [23].
While safety is the primary objective for both Phase 
Ia/Ib clinical trials, each team has also defined clinical 
trial secondary and exploratory objectives to evaluate 
both the immunogenicity of the respective vaccines and 
the functionality of antibody responses. The analysis of 
the humoral immune response, the amplitude (the level 
of vaccine-induced antibodies), is a secondary objective 
common to both teams. The common exploratory objec-
tives are the assessment of the quality of the immune 
response, measured as functional inhibition activity of 
the antibodies, and the assessment of cytokine produc-
tion by immune cells after ex  vivo stimulation with the 
respective vaccine antigens.
Methods
The implementation of common standard operating pro-
cedures, reagents, reference standards, equipment and 
exchange of material/expertise by the UCPH and Inserm 
teams will be coordinated and supported by EVI. This is 
advantageous to both teams and to the entire placental 
malaria vaccine community, as it will establish bench-
marks for the immunoassays and contribute to the reli-
ability of the data. One key issue was the selection of 
assays to be used to quantify immunogenicity, to evalu-
ate preliminary efficacy, and to produce the most reliable 
data for go/no-go decision-making during later stages of 
the clinical development.
Reference standards
In order to standardize the immunoassays used in the 
clinical trials, both teams agreed on using reference 
standards consisting of pools of sera/plasma isolated 
from (1) multigravid women living in malaria endemic 
areas and highly reactive towards VAR2CSA variants 
(positive pool) and (2) women never exposed to Plasmo‑
dium, thus presenting no or very low reactivity against 
VAR2CSA (negative pool). Questions were raised regard-
ing the size and conditioning of the different pools, their 
maximal storage duration and the number of clinical tri-
als for which they could be used as reference standards. 
Based on the panel consensus, Inserm and UCPH teams 
will estimate the amount needed for their Phase Ia/Ib 
clinical trials, with an expectation that the pools will be 
expanded for future related Phase II clinical trials. Of 
note, groups other than Inserm and UCPH could also 
benefit from established reference standards for their 
own vaccine development processes. The UMR216 unit 
of the Institut de recherche pour le développement (IRD), 
based in Paris, will assemble the positive pool consisting 
of sera from multigravid Beninese women whereas the 
negative pool from unexposed women will be provided 
by the Bichat Hospital (France).
Immunogenicity
Antibody levels by  ELISA Assessment of the vaccine-
induced VAR2CSA-specific total IgG levels by ELISA is a 
secondary objective common to both projects. In addition 
to the evaluation of the amplitude of the humoral immune 
response elicited by vaccination, levels of VAR2CSA-spe-
cific total IgGs will also define the percentage vaccines 
who seroconvert, a criterion to proceed to a Phase II clini-
cal trial. The advantages of the ELISA are its robustness 
and its amenability to automation, standardization and 
harmonization and easy transfer of protocols/standard 
operating procedures (SOPs) between different laborato-
ries. ELISA has been extensively used by both teams in 
pre-clinical studies and was proven as adequate to detect 
naturally acquired human antibodies directed towards 
Table 2 Major outcomes on the design of the Phase Ia/Ib clinical trials
• The clinical trial fast track strategy could be implemented where the Phase Ia and the Phase Ib will be staggered into a single clinical trial
• The clinical trial population from non-endemic areas will include male and female healthy adults
• The clinical trial population from endemic regions will be restricted to healthy nulligravid females with an upper age limit of 35 years and a lower age 
limit to be set according to the laws of majority governing the trial site
• The clinical trial will assess three dosages and the appropriate dosage of vaccine antigen will be around 50 µg
• Adjuvant would include aluminium hydroxide and a novel adjuvant.
• Placebo will be used in the malaria endemic-population
• The immunization schedule was agreed—three intramuscular doses will be administered at 0, 1 and 2 months
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VAR2CSA-based proteins, such as the ones comprising 
the current vaccine candidates [27, 28].
Harmonization of the ELISA is essential in order to 
generate reliable and comparable data. Careful stand-
ardisation will be performed using the common refer-
ence standards and exchange of SOPs. Common blood 
sampling time-points will be used, at baseline (before 
any vaccination), 1  month after each immunization 
(three immunizations are scheduled at 1  month inter-
vals), and 4 and 7  months after the last immunization. 
While vaccine-induced VAR2CSA-specific total IgG 
levels in malaria-naive subjects should be straightfor-
ward to assess, workshop attendees discussed the inter-
fering effect of background reactivity in volunteers from 
malaria endemic areas. Naturally acquired antibodies 
directed to other, non-pregnancy related PfEMP1 vari-
ants, might cross-react with the immunizing antigens, 
and thereby mask the specific ELISA signal induced by 
vaccination. In light of this possibility, ELISA data will be 
interpreted with extreme care in order to draw appropri-
ate conclusions.
A major limitation of the ELISA is nevertheless its 
inability to determine if the detected antibodies are func-
tionally active and contribute to protection against pla-
cental malaria. ELISA must therefore be complemented 
by other techniques to properly address this issue.
Functional analysis
Antibody inhibitory activity by  CSA‑binding inhibition 
assays In order to facilitate the comparison of the vac-
cine candidates, both teams agreed to unify some func-
tional assays. Of major importance, the CSA-binding 
inhibition assay (BIA) allows a qualitative analysis of 
the functional antibody response elicited by the vaccine 
candidate. The BIA assesses the capability of immune 
sera (more specifically of the IgG component) to block 
the interactions between placental type P. falciparum-
infected erythrocytes and CSA.
The UCPH and Inserm teams routinely perform the 
well-established Petri dish BIA method [29] as well as a 
high throughput technique based on the use of 96-well 
microtitre plates [30]. In both approaches, CSA is coated 
on a plastic substrate as a platform for binding of infected 
erythrocytes, and BIA with sera or other inhibitors are 
performed under static conditions (Fig. 1). Even though 
the more relevant ex  vivo placental perfusion model 
performed under flow conditions is available in both 
laboratories, this methodology is not yet designed for 
processing numerous samples and is difficult to imple-
ment under field conditions [31]. The vaccine teams, 
therefore, agreed to use the Petri dish BIA method as a 
common reference technique to allow comparison of 
results between the studies. Each team will run their own 
96-well microtitre plate methods in parallel as they offer 
the possibility to run many replicates thus increasing the 
statistical power of the data sets. Furthermore, the com-
parative analysis of both methods might allow the design/
optimization and validation of a high throughput BIA 
that could be used in future clinical trials, such as Phase 
II clinical trials, when the number of samples to be pro-
cessed might exceed the capacities of the classical Petri 
dish assay. UCPH and Inserm agreed on sharing SOPs for 
both types of BIA.
The choice of the P. falciparum strains to be used in the 
BIA has been extensively discussed between the members 
of the different projects. The PRIMALVAC and PAM-
CPH/PlacMalVac have designed their vaccines based on 
the 3D7-VAR2CSA and FCR3-VAR2CSA parasite strain 
sequences, respectively. It was obvious that both 3D7 and 
FCR3 strains expressing VAR2CSA should be included 
in the BIA. FCR3 and 3D7 [32, 33] are two well-charac-
terized, fully sequenced, laboratory adapted cloned para-
sites lines. Erythrocytes infected by either FCR3 (also 
known as IT4) or NF54 (parental clone of 3D7) are easy 
to select for VAR2CSA surface expression by panning on 
CSA [34]. In order to further assess the cross-inhibitory 
capability of antibodies generated following vaccination, 
Fig. 1 Infected erythrocytes bound to CSA-coated Petri dishes. 
(kindly provided by: Marilou Tétard, Inserm)
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a third in  vitro adapted cloned parasite line, 7G8, that 
originates from a different part of the world (Brazil) will 
be included in BIA.
Fresh placental parasite isolates will also be incorpo-
rated in this analysis, as they represent parasite popula-
tions from the field sites and geographical areas where 
the vaccine will be implemented. Workshop attendees 
agreed that three fresh parasite isolates will be sufficient 
to extend the parasite panel used in the BIA.
For a selected subject, activity in a pre-immune sample 
appears be the most appropriate negative control for this 
type of assay. As with ELISA measurements, the investi-
gators expect minimal background in the European sam-
ples by BIA, but inhibitory background may be present 
in some pre-immune samples from Africa due to existing 
immune responses to malarial antigens, potentially inter-
fering with quantification of vaccine-induced responses. 
Aware of this possibility, both teams will interpret the 
generated BIA data in light of pre-existing activity.
Antibody reactivity to the surface of placental‑type infected 
erythrocytes by  flow cytometry While antibodies that 
inhibit binding of placental type P. falciparum-infected 
erythrocytes to CSA appear to be a primary protective 
feature, assessing the reactivity of antibodies to the native 
VAR2CSA expressed at the infected red blood cell sur-
face is also informative. Indeed, the antibody levels deter-
mined by ELISA rely on the use of recombinant proteins 
as target antigens and might not fully reflect reactivity to 
native VAR2CSA. Such analyses will also allow assess-
ments of cross-recognition of different native VAR2CSA 
variants from parasites of different geographical origins. 
Furthermore, opsonization of infected erythrocytes could 
potentially trigger a variety of immune effecter mecha-
nisms such as opsonic phagocytosis, antibody-dependent 
cellular cytotoxicity (ADCC) and complement depend-
ent cytotoxicity (CDC). Even though the relative impor-
tance of such mechanisms in protection against placental 
malaria is still unclear, the generated data will be useful 
to better understand the complexity of immune processes 
taking place during P. falciparum infection in pregnancy.
Both teams agreed to perform a flow cytometry-based 
analysis of cell surface reactivity of vaccine-induced 
VAR2CSA-specific IgGs to placental-type infected eryth-
rocytes. Ideally the panel of parasite lines to be included 
in this type of analysis should be consistent with that 
used for the binding inhibition assays. Despite the use 
of common SOPs and due to unavoidable differences in 
the flow cytometry equipment, slight variations between 
each team’s results are anticipated.
Cell‑mediated immune response While titers of circu-
lating vaccine antigen-specific antibodies are a robust 
indicator of immunogenicity and induction of humoral 
immune responses, this type of measurement should ide-
ally be complemented by the assessment of cell-mediated 
immune responses. Enzyme-linked immunospot (ELIS-
pot) assays are now widely used to monitor adaptive 
immune responses in humans and permit a quantitative 
as well as a qualitative analysis of T cells [35]. In a T cell 
ELISpot assay, each spot represents a cytokine secreting 
cell allowing the determination of the frequency of T cells 
responding to a stimulatory antigen. The PRIMALVAC 
team is planning to perform T cell ELISpot to quantify 
cytokine-producing T cells after stimulation with the vac-
cinating antigen DBL1X–DBL2X. Meanwhile, the super-
natant of stimulated peripheral blood mononuclear cells 
(PBMCs) cultures will be used for the quantification of 
a larger panel of cytokines using a flow cytometry-based 
multiplex assay. Protocols will be shared by the teams as 
part of the harmonization process.
Kinetics and breadth of  the immune response In terms 
of longitudinal assessment, a possible approach would be 
to follow women for at least 6 months after the last vac-
cine boost, and ideally until the first pregnancy. An ongo-
ing baseline study in Benin is suggesting that as many as 
25 % of women could become pregnant within 12 months 
after enrollment, and that 30–40 % of them are likely to be 
infected with P. falciparum during pregnancy. Therefore a 
careful design and sufficient additional funds for the fol-
low-up studies for both clinical trials (PRIMALVAC and 
PlacMalVac) will be required to study the natural boosting 
effects. To study the breadth of the immune response, the 
B cell memory immune response will either be assessed 
using a B cell ELISpot assay or by performing B cell phe-
notyping as exploratory endpoints. A summary of the 
immunoassays to be performed in each of the projects is 
provided in Tables 3 and 4. 
Discussion and conclusion
Currently, treatment and prevention of placental malaria 
relies on the use of long-lasting insecticide-impregnated 
nets and sulfadoxine–pyrimethamine (SP)-based IPTp 
strategies. Resistance of parasites to drugs and of mos-
quitoes to insecticides, are increasingly compromising 
the effectiveness of these tools. In addition, placental 
malaria is very often sub-clinical, with parasitaemia at 
very low (sub-microscopic) levels, such that pregnant 
women often remain unaware of their infection and 
do not seek treatment. At their first antenatal visit, and 
therefore their first SP dose, many pregnant women have 
already sustained infections and suffered sequelae of pla-
cental malaria. Further, SP is contraindicated in the first 
weeks and months of pregnancy due to potentially seri-
ous clinical consequences for the fetus. Looking forward, 
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the costs and logistical challenges of mass drug adminis-
tration to pregnant women cannot be ignored and new 
methods for malaria control during pregnancy urgently 
need to be explored.
A malaria vaccine that rapidly controls blood-stage 
infection and prevents sequelae would be an excel-
lent tool to protect women against placental malaria. 
GlaxoSmithKline’s RTS,S/AS01 (Mosquirix™) by far the 
most advanced malaria vaccine, has been developed for 
administration to children. RTS,S/AS01 provides about 
36 % protection against blood-stage infections and clini-
cal malaria over 1 year to children aged 5–17 months at 
first immunization but vaccine efficacy fell to less than 
5 % from the fourth year [36–39]. The protection is short-
lived, waning over some months as antibody levels rap-
idly decline after vaccination. Even if RTS,S/AS01 were 
developed for pregnant women, it only confers partial 
protection in children and perhaps less in adults, so its 
potential activity against placental malaria is uncer-
tain. Additional tools are required to combat placen-
tal malaria. Vaccines designed specifically for placental 
malaria are attractive because they could lead to reduc-
tions both in disease incidence and severity.
The two placental malaria vaccine candidates, PAM-
VAC and PRIMVAC adjuvanted with Alhydrogel 
(Brenntag, Denmark), GLA-SE or GLA-LSQ (IDRI, 
USA) entered Phase Ia/b clinical trials in May 2016 
(NCT02647489, NCT02658253). To allow comparison 
of the clinical trial results and to enable informed deci-
sion making for further development, two workshops 
were conducted by EVI with the aim of standardizing 
and harmonizing the clinical development plans and the 
immunoassays for assessing responses to the two placen-
tal malaria vaccine candidates. The workshop on clinical 
development defined the main preferred product charac-
teristics, the clinical development plan and in more detail 
the design of the Phase Ia/b clinical trials. The second 
workshop on immunoassay harmonization targeted the 
definition of reference reagents and standards to be used 
to evaluate vaccine candidate performance. Harmonized 
ELISA will be performed to assess antibody levels gen-
erated by vaccination and the criterion for transition to 
Phase II requires at least 60  % seroconversion against 
the vaccine candidate antigen in the target population. 
Exploratory objectives include the analyses of the (1) 
antibody inhibitory activity in CSA-binding inhibition 
assays, (2) antibody reactivity to the surface of placental-
type infected erythrocytes by flow cytometry, (3) cell-
mediated immune response, and (4) kinetics and breadth 
of the immune response.
The results of the Phase Ia/b clinical trials for the two 
vaccine candidates will be used to further refine and opti-
mize the Phase IIb clinical trial design. Evaluation cri-
teria for Phase IIb efficacy testing will be set according 
to the Phase Ia/b clinical trial results, the results of on-
going baseline study in Benin, planned anti-malarial drug 
trials to evaluate different drug regimens in placental 
malaria, as well as results of studies performed by NIH 
in collaboration with the EVI, Inserm and UCPH teams 
to validate an Aotus monkey placental malaria model. In 
Phase II clinical trials, pregnant women will be followed 
as recommended by the respective Ministries of Health, 
and blood samples for immunological analyses will be 
collected at each antenatal visit and at delivery. Evalua-
tion criteria will take into account maternal disease and 
birth outcomes. Rather than proceeding directly to large 
Phase IIb efficacy trials upon satisfactory safety and 
immunogenicity results in the Phase Ia/b clinical trials, 
a Phase Ib–IIb bridging clinical trial without an efficacy 
endpoint might be considered to optimize vaccine dos-
age. This would allow studies of (1) the longevity of the 
induced antibody response, (2) the need for a booster 
immunization, (3) the extent to which a long-lasting anti-
body response targets different VAR2CSA antigenic vari-
ants, (4) the duration of the memory response that can be 
boosted by infection; and (5) the utility of a prime-boost 
or association regimen in eliciting a broader immune 
response in vaccinated women after natural infection.
In summary, the development of placental malaria 
vaccines will require continuous collaboration, 
Table 3 Immunoassays performed in the PRIMALVAC and PlacMalVac projects: secondary objectives
PRIMALVAC PlacMalVac
Secondary objectives Immunoassays Secondary objectives Immunoassays
Total IgG and subtypes (IgG1, IgG2, IgG3, IgG4) ELISA Total IgG ELISA
T cell cytokine production T cell ELISpot after ex vivo stimulation of PBMCs with 
vaccine antigen
B lymphocytes phenotyping Flow cytometry
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standardization and harmonization among the teams to 
allow the further development of the most suitable and 
best performing vaccine candidate.
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